Study of Ketamine Administered Intravenously and by Sublingual Wafer

Brief Summary

To determine the rate and extent of of absorption of racemic ketamine from sublingual wafer

Intervention / Treatment

Condition or Disease

  • Pain

Phase

Study Design

Study type: Observational
Status: Completed
Study results: No Results Available
Age: 18 Years to 65 Years   (Adult, Older Adult)
Enrollment: 8 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Jun 11, 2020
Primary Completion: Jun 11, 2020
Completion Date: Jun 11, 2020
Study First Posted: Jun 21, 2011
Results First Posted: Aug 31, 2020
Last Updated: Mar 10, 2015

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

  1. To determine the apparent rate of disintegration of the sublingual wafer
  2. To determine the overall clinical tolerability of ketamine when administered as a single dose via the sublingual route. Tolerability will be assessed using a range of objective and subjective parameters as assessed using modified Likert and Bond and Lader scales.

Eligibility Criteria

Sex: Male
Minimum Age: 18
Maximum Age: 65

More Details

NCT Number: NCT01377831
Other IDs: KET001
Study URL: https://ClinicalTrials.gov/show/NCT01377831
Last updated: Feb 22, 2021